



November 4, 2022

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street, Fort  
Mumbai - 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400 051

Scrip Code: **530019**

Symbol: **JUBLPHARMA**

Dear Sirs,

**Sub: Compliance under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of the Related Party Transactions in the prescribed format for half year ended September 30, 2022.

We request you to take the same on record.

Thanking you,

Yours faithfully,  
For Jubilant Pharmova Limited

Naresh Kapoor  
Company Secretary

Encl.: As above

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Pharmova Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
UP, India  
CIN : L24116UP1978PLC004624





































Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee (Refer Note 2)	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.												
	Name	PAN (refer Note 3)	Name	PAN (refer Note 3)	Relationship of the counterparty with the listed entity or its subsidiary						In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments											
											Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment )	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)				
393	Jubilant Discovery Services LLC		Jubilant Pharma Holdings Inc.		Fellow subsidiary	Any other transaction	Reimbursement Of Expenses		None	0.63	0	0													
394	Jubilant Cadista Pharmaceuticals Inc.		Jubilant DraxImage Inc.		Fellow subsidiary	Any other transaction	Trade and other receivables		None	0.00	0.41	0													
395	Jubilant Cadista Pharmaceuticals Inc.		Jubilant HollisterStier General Partnership		Fellow subsidiary	Any other transaction	Trade and other receivables		None	0.00	0.28	0													
396	Jubilant Cadista Pharmaceuticals Inc.		Jubilant HollisterStier LLC		Fellow subsidiary	Any other transaction	Trade and other receivables		None	0.00	20.07	30													
397	Jubilant Cadista Pharmaceuticals Inc.		Jubilant Ingrevia Limited		Enterprise in which Key management personnel are interested	Any other transaction	Trade and other payables		None	0.00	0	0.87													
398	Jubilant Cadista Pharmaceuticals Inc.		Jubilant Pharma Holdings Inc.		Immediate parent	Any other transaction	Trade and other receivables		None	0.00	120.89	0													
399	Jubilant Cadista Pharmaceuticals Inc.		Jubilant Pharma Limited		Intermediate parent	Any other transaction	Trade and other receivables		None	0.00	6.76	9.13													
400	Jubilant Cadista Pharmaceuticals Inc.		Jubilant Pharma ME FZ- LLC		Fellow subsidiary	Loan			None	0.00	0	8.14													
401	Jubilant Cadista Pharmaceuticals Inc.		Jubilant Pharma Limited		Intermediate parent	Interest received			None	1.79	0	0													
402	Jubilant Cadista Pharmaceuticals Inc.		Jubilant Pharma ME FZ- LLC		Fellow subsidiary	Interest received			None	0.01	0	0													
403	Jubilant Cadista Pharmaceuticals Inc.		Jubilant DraxImage Inc.		Fellow subsidiary	Any other transaction	Recovery of Expenses		None	3.48	0	0													
404	Jubilant Cadista Pharmaceuticals Inc.		Jubilant HollisterStier General Partnership		Fellow subsidiary	Any other transaction	Recovery of Expenses		None	3.22	0	0													
405	Jubilant Cadista Pharmaceuticals Inc.		Jubilant HollisterStier LLC		Fellow subsidiary	Any other transaction	Recovery of Expenses		None	8.06	0	0													
406	Jubilant Cadista Pharmaceuticals Inc.		Jubilant Ingrevia Limited		Enterprise in which Key management personnel are interested	Any other transaction	Reimbursement Of Expenses		None	1.70	0	0													
407	Jubilant Cadista Pharmaceuticals Inc.		Jubilant Pharma Holdings Inc.		Immediate parent	Any other transaction	Borrowings Repaid		None	12.56	0	0													
408	Jubilant Cadista Pharmaceuticals Inc.		Jubilant Pharma Holdings Inc.		Immediate parent	Any other transaction	Borrowings Taken		None	538.32	0	0							Loan	0.045	4 Years	Unsecured	Business purpose		
409	Jubilant Cadista Pharmaceuticals Inc.		Jubilant Pharma ME FZ- LLC		Fellow subsidiary	Any other transaction	Loans given		None	7.85	0	0							Inter-corporate deposit	0.0305	2 Years	Unsecured	Business purpose		
410	Drug Discovery and Development Solutions Limited		Jubilant Biosys Innovative Research Services Pte Limited		Step down subsidiary	Any other transaction	Trade and other receivables		None	0.00	0.37	0													
411	Drug Discovery and Development Solutions Limited		Jubilant Innovation (USA) Inc.		Subsidiary	Any other transaction	Trade and other receivables		None	0.00	0	0.17													
412	Drug Discovery and Development Solutions Limited		Jubilant Therapeutics Inc.		Fellow subsidiary	Any other transaction	Interest receivable on loans		None	0.00	0	36.1													
413	Drug Discovery and Development Solutions Limited		Jubilant Therapeutics Inc.		Fellow subsidiary	Interest received			None	34.87	0	0													
414	Draxis Pharma LLC		Jubilant HollisterStier Inc.		Immediate parent	Loan			None	0.00	18.72	20.09													
415	Drug Discovery and Development Solutions Limited		Jubilant Therapeutics Inc.		Fellow subsidiary	Investment			None	313.89	0	0	Loan		0.035	4 Years	Investment		0.03	5 Years	Unsecured	Business purpose			
416	Jubilant Therapeutics Inc.		Jubilant Epicore LLC		Subsidiary	Investment			None	66.70	0	0	Any other	Issuance of convertible promissory notes	0.03	5 Years	Investment		0	Not applicable	Unsecured	Business purpose			

Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee (Refer Note 2)	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
	Name	PAN (refer Note 3)	Name	PAN (refer Note 3)	Relationship of the counterparty with the listed entity or its subsidiary						In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments								
											Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment )	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	
417	Jubilant Therapeutics Inc.		Jubilant Epipad LLC		Subsidiary	Investment			None	15.69	0	0	Any other	Issuance of convertible promissory notes	0.03	5 Years	Investment	0	Not applicable	Unsecured	Business purpose	
418	Jubilant Therapeutics Inc.		Jubilant Episcrbe LLC		Subsidiary	Investment			None	27.47	0	0	Any other	Issuance of convertible promissory notes	0.03	5 Years	Investment	0	Not applicable	Unsecured	Business purpose	
419	Jubilant Therapeutics Inc.		Jubilant Prodel LLC		Subsidiary	Investment			None	35.31	0	0	Any other	Issuance of convertible promissory notes	0.03	5 Years	Investment	0	Not applicable	Unsecured	Business purpose	
420	Jubilant Therapeutics Inc.		Jubilant Epicore LLC		Subsidiary	Any other transaction	Recovery of Expenses		None	11.38	0	0										
421	Jubilant Therapeutics Inc.		Jubilant Epipad LLC		Subsidiary	Any other transaction	Recovery of Expenses		None	9.55	0	0										
422	Jubilant Therapeutics Inc.		Jubilant Episcrbe LLC		Subsidiary	Any other transaction	Recovery of Expenses		None	27.98	0	0										
423	Jubilant Therapeutics Inc.		Jubilant Prodel LLC		Subsidiary	Any other transaction	Recovery of Expenses		None	11.37	0	0										
424	Jubilant HollisterStier General Partnership		Jubilant Ingrevia Limited		Enterprise in which Key management personnel are interested	Any other transaction	Reimbursement of expenses		None	1.26	0	0										
425	Jubilant DraxImage Limited		Jubilant Ingrevia Limited		Enterprise in which Key management personnel are interested	Any other transaction	Trade and other payables		None	0.00	0.01	0.01										
<b>Total value of transaction during the reporting period</b>										<b>47486.48</b>												

**Notes:**  
1) As the liabilities for the gratuity and compensated absences are provided on an actuarial basis, and calculated for the Company as a whole, the said liabilities pertaining specifically to KMP are not known and hence, not included in the above information.  
2) The value of the related party transaction denotes the amount approved by the Audit Committee/ Board of Directors of Jubilant Pharmova Limited as applicable, for financial year 2022-23  
3) As per the circular for disclosure of related party transactions dated 25 April 2022, issued by the Stock Exchanges, since the Company is filing the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.